Doxepin, a tricyclic antidepressant (TCA) used to treat depression, anxiety disorders, and insomnia, was developed in the 1960s and approved for medical use in the late 1960s. Its history is marked by its effectiveness in alleviating depressive and anxiety symptoms, as well as managing chronic insomnia, but also by its risk of anticholinergic side effects, sedation, and cardiac toxicity, which has led to careful dose monitoring and caution in vulnerable populations. Doxepin, a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, was approved in the United States in 1969 and has been included in various treatment regimens for major depressive disorder, anxiety, and sleep disturbances. Its development involved extensive clinical trials to establish safety, efficacy, and tolerability, and its use is guided by careful titration to balance therapeutic benefits with potential adverse effects.
BRAND NAMES
Sinequan – widely used for depression and anxiety.
Adapin – an alternative brand for depression and anxiety.
MECHANISM OF ACTION
Doxepin is a tricyclic antidepressant (TCA) that primarily works by inhibiting the reuptake of norepinephrine and serotonin in the central nervous system. This action increases the concentration of these neurotransmitters in the synaptic cleft, enhancing neurotransmission and improving mood and anxiety symptoms.
PHARMACOKINETICS
Absorption
Doxepin is well absorbed orally, with peak plasma concentrations occurring 2–6 hours after administration. Bioavailability is affected by first-pass hepatic metabolism, resulting in moderate systemic exposure.
Distribution
Doxepin is widely distributed throughout the body, with a volume of distribution (Vd) of approximately 10–20 L/kg. It is highly protein-bound (≈95%), and penetrates the central nervous system effectively to exert its therapeutic effects.
Metabolism
Doxepin undergoes extensive hepatic metabolism, primarily through cytochrome P450 enzymes (CYP2D6 and CYP2C19), forming active metabolites such as desmethyldoxepin, which contribute to its antidepressant and anxiolytic effects.
Elimination
The drug and its metabolites are primarily excreted via the urine, with a smaller fraction eliminated in feces. The elimination half-life ranges from 15 to 30 hours, allowing for once- or twice-daily dosing depending on the indication and formulation.
PHARMACODYNAMICS
Doxepin exerts its therapeutic effects through enhancement of serotonergic and noradrenergic neurotransmission by inhibiting the reuptake of serotonin (5-HT) and norepinephrine (NE) at synaptic terminals. This action helps alleviate depressive symptoms, anxiety, and mood disturbances.
ADMINISTRATION
Doxepin is administered orally or topically depending on the indication. For depression and anxiety, it is given as oral tablets or capsules, typically starting at 25–75 mg per day, taken once or twice daily, usually at bedtime due to its sedative effects. The dose can be gradually increased according to clinical response and tolerability.
DOSAGE AND STRENGTH
Doxepin is available in multiple formulations depending on the indication. For depression and anxiety, oral tablets or capsules are typically 25 mg, 75 mg, 100 mg, and 150 mg, with a usual starting dose of 25–75 mg per day, gradually titrated to 100–150 mg per day as tolerated. For insomnia, low-dose oral capsules (Silenor) are available in 3 mg and 6 mg, taken at bedtime.
DRUG INTERACTIONS
Doxepin interacts with several medications due to its effects on the central nervous system and hepatic metabolism via cytochrome P450 enzymes (CYP2D6 and CYP2C19). Concomitant use with other CNS depressants such as alcohol, benzodiazepines, opioids, or antihistamines may enhance sedation, drowsiness, and impaired motor coordination.
FOOD INTERACTIONS
Doxepin can be taken with or without food, as meals do not significantly affect its absorption or therapeutic efficacy. However, patients should avoid alcohol, as it can increase sedation, drowsiness, and impair coordination when combined with doxepin.
CONTRAINDICATIONS
Doxepin is contraindicated in patients with known hypersensitivity to doxepin, other tricyclic antidepressants, or any component of the formulation. It should not be used in individuals with a recent myocardial infarction, severe heart block, or arrhythmias, due to the risk of cardiotoxicity.
SIDE EFFECTS
Sedation or drowsiness
Dry mouth
Blurred vision
Constipation
Urinary retention
Dizziness or lightheadedness
Weight gain
OVER DOSAGE
Overdose of Doxepin can be serious and potentially life-threatening, primarily due to itseffects on the cardiovascular and central nervous systems. Symptoms may include severe drowsiness, confusion, agitation, seizures, hypotension, cardiac arrhythmias, and respiratory depression.
TOXICITY
Doxepin exhibits high toxicity in overdose, primarily affecting the cardiovascular and central nervous systems. Even moderate overdoses can lead to arrhythmias, hypotension, and respiratory depression, while severe overdoses carry a high risk of fatal outcomes, particularly in children and elderly patients. Neurological effects may include confusion, agitation, seizures, and coma. Chronic use at therapeutic doses can also produce anticholinergic toxicity, resulting in dry mouth, constipation, urinary retention, blurred vision, and sedation.
